Drugs / Multiple sarcoma-specific CAR-T cells
Multiple sarcoma-specific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04433221 | Jul 2026 → May 2029 expected | Ewing sarcoma, osteosarcoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multiple sarcoma-specific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04433221 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT04433221 ↗ |
| Route | Intravenous | “via IV” NCT04433221 ↗ |